Atherosclerosis is the main underlying cause of cardiovascular disease (CVD) and due to its multifactorial natural is often studied in animal models. Here the aim is to develop an innovative ex vivo system to study the atherosclerotic disease process based on the actual human atherosclerotic plaque. In line with the Transition to Animal-free Innovation (TPI), the aim is to develop a model that generates data on the effect of novel drugs that is highly translatable to the effect of the novel drug in the cardiovascular patient, while at the same time minimising the number of laboratory animals used. Moreover, the aim is to utilise this model to discover new biomarkers of successful treatment, which could expedite the transition of CVD therapeutic into clinical trial.
The IMAGEN consortium aims to improve diagnostics of patients with ciliopathies and tubulopathies, enhance quality of care, and translate genetic findings to personalised care by testing pharmacological treatment approaches based on patient-derived disease models.
The RBD‐CURE project will develop innovative gene therapy approaches for patients with rare bleeding disorders. The unique expertise of Sanquin on bleeding disorders together with the advanced gene therapy strategies developed by SanaGen and the Netherlands Institute for Neurosciences aims to provide a permanent cure for patients with rare bleeding disorders.
The cancer grade, provided by pathologists, is the most important predictor of patient outcome, but suffers from inter- and intra-pathologist variability, reducing its usefulness for individual patients. An expert-level AI system will be provided to support pathologist and help reduce this variability and make their diagnostic practice more accurate and efficient.
The knowledge is missing that is essential for cost-effective roll-out of personalised treatment of insomnia. This project solves the bottleneck by creating a research platform for combined online behavioural change intervention and long-term monitoring of sleep, traits and health. A growing database will allow for optimised sleep interventions tailor to personalised needs, capacities, limitations and estimated benefits.
The immune system has potent mechanisms with which it deals with intruding viruses, bacteria and tumors, protecting us from disease. However, tumors contain mutations leading to resistance to the immune system. The NextIO project aims to develop a medicine that restores the sensitivity of the cancer to the immune system.
This project aims to unravel mechanisms underlying beneficial effects of a novel food supplement on cognitive performance. This may contribute to the prevention of cognitive impairment and ultimately dementia. Focus will be on adults with an emerging pre-mild cognitive impairment condition who will benefit most from evidence-based intervention and prevention strategies.
Replacing current invasive testing by a simple blood test to enable prenatal diagnosis for pregnant couples carrying severe monogenic diseases, is much desired. In this project the aim is to develop an efficient NIPD method for monogenic diseases, for implementation in the clinic.
Acute myeloid leukemia (AML) is a form of blood cancer that is still difficult to cure and better therapies against AML are clearly needed. As a continuation of a long-standing collaboration between the Schuringa lab at the UMCG and Janssen will exploit potential novel targets against leukemic stem cells.
Increasing evidence suggests that dynamic changes in the transcriptional state of specific cell-types plays a key role in determining disease outcomes. Here, cell-type specific changes will be detected in tuberous sclerosis complex cortical tubers and assessed if these cell-type changes are involved in the pathogenesis of epilepsy.